Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-649868 in Primary Insomnia
NCT00426816Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2006
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Formulation D in Insomnia, sponsored by GSK. Primary endpoints: Total Sleep Time at 9 weeks, Latency to Persistent Sleep at 9 weeks and 1 more. Started Dec 2006; status: completed.
02
Drugs
Formulation D
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT00426816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00426816.